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The incidence of psychosis during clinical trials of topiramate was 0.8%, not significantly different from the rate for placebo
or reported rates of psychosis in patients with refractory epilepsy. We observed psychotic symptoms in five patients soon after
initiation of topiramate therapy. We performed a retrospective chart review of the first 80 patients who began on topiramate
after approval for clinical use, between January and April 1997. Symptoms suggestive of psychosis, including hallucinations
and delusions, were sought for analysis. Cognitive effects such as psychomotor slowing, confusion, and somnolence were not
included. Five patients developed definite psychotic symptoms 2 to 46 days after beginning topiramate. Dosages at symptom onset
were 50–400 mg/day. Symptoms included paranoid delusions in four patients and auditory hallucinations in three. Symptoms of
psychosis and other psychiatric symptoms resolved quickly with discontinuation of topiramate in three patients, dose reduction
from 300 to 200 mg/day in one and with inpatient treatment and neuroleptics in another. One patient had a history of auditory
hallucinations, one of aggressive and suicidal thoughts, but three had no significant psychiatric history. Physicians should be aware
of the possibility of psychotic symptoms, even in patients without a previous psychiatric history, when prescribing topiramate.
Symptoms resolve quickly with discontinuation.
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Various central nervous system side-effects are com-
mon with the use of antiepileptic drug therapy in
patients with epilepsy. Symptoms suggestive of psy-
chosis in some patients with epilepsy have been at-
tributed to the use of vigabatrin1, carbamazepine, val-
proic acid, ethosuximide2 and phenacemide3. Topira-
mate is a highly effective new antiepileptic drug when
used as an adjunctive therapy in patients with refrac-
tory partial seizures. Mild to moderate cognitive im-
pairments have been described as the main side-effects
of this drug. The incidence of psychosis was not sig-
nificantly different among treatment groups compared
to placebo groups in premarketing clinical drug trials.
We discuss five patients treated with topiramate who
developed symptoms of psychosis. These included the
sudden onset of various combinations of paranoid delu-
sions, auditory hallucinations and a feeling of deper-
sonalization. Suicidal thoughts, aggressive and agitated
behavior and thoughts, severe mood swings or cogni-
tive problems were often present as well, but were not
considered evidence of psychosis by themselves.1059–1311/99/040235 + 03 $12.00/0Materials and methods
We performed a retrospective chart review of the first
80 patients with partial seizures put on topiramate af-
ter approval for clinical use from 16 January 1997 to
15 April 1997 at the University of Alabama at Birming-
ham Epilepsy Center. Patients who developed symp-
toms of psychosis such as hallucinations and delusions
were included. Patients with cognitive impairment such
as slowed thinking, psychomotor slowing, language
impairment, confusion, symptoms of depression, cry-
ing spells, and impairment of sleep were not included.
Five patients with a history of partial seizures, aged
27 years to 62 years, three men and two women, met
criteria for a diagnosis of psychosis.
Case 1
A 27-year-old woman had a history of refractory com-
plex partial seizures since birth secondary to an hy-
pothalamic hematoma. She had no history of psychi-
atric illness. Her seizure frequency was 1–2 per day
despite treatment with optimal doses of carbamazepinec© 1999 BEA Trading Ltd
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men beginning with 50 mg q.d. with a titration rate
of 50 mg every week. At a dose of 150 mg/day, she
had the sudden onset of paranoia with fear of being
observed and being followed all the time. Because of
this, the patient was afraid to leave her house. Other
side-effects included worsening unsteadiness of gait,
dizziness, and impairment of concentration and mem-
ory. Her seizure frequency improved during treatment
with topiramate. The symptoms of paranoid ideation
resolved completely within 48 hours after discontinu-
ation of topiramate.
Case 2
A 62-year-old woman had a history of complex par-
tial seizures since five years of age. She had no his-
tory of psychiatric illness. She had been seizure-free
for 2.5 years on phenytoin before a seizure two days
before topiramate was introduced. Topiramate was be-
gun at 25 mg q.d. and increased at a rate of 25 mg
each week for the first four weeks. Symptoms of psy-
chosis and paranoia developed at a dose of 150 mg b.i.d.
(300 mg/day). These consisted of remaining awake all
night hearing voices, and accusing her husband of at-
tempting to kill her. She repeatedly complained of in-
truders within the house. Six weeks after the introduc-
tion of topiramate she developed onset of psychotic
symptoms while she continued to be seizure-free dur-
ing this period. Resolution of symptoms was seen with
reduction of the topiramate dose to 100 mg twice a
day (200 mg/day), and she was continued on topira-
mate.
Case 3
A 50-year-old man had a history of post-traumatic sec-
ondarily generalized tonic–clonic seizures since the
age of six years. He had a long standing history of
auditory hallucinations and mild depression that had
never been treated. His last seizure was 2.5 months
prior to topiramate therapy. Topiramate was added to
phenytoin at a dose of 50 mg q.d. In the fourth week of
therapy, clinically overt hallucinations developed and
his depression worsened. He heard voices that spoke
against him and told him to hurt his wife, that had never
happened before. He also had worsening of symptoms
of depression including suicidal thoughts. He remained
seizure-free during topiramate therapy. A marked im-
provement in these symptoms of psychosis was noted
within 24 hours after discontinuation of topiramate and
treatment with haloperidol.Case 4
A 46-year-old man had a 12-year history of post-
traumatic complex partial seizures. He had no history
of psychiatric illness. His seizure frequency was one
per month on no antiepileptic medication. Topiramate
was begun at a dose of 50 mg q.d. with a titration
rate of 50 mg increase each week. Symptoms of psy-
chosis developed at a topiramate dose of 75 mg b.i.d.
(150 mg/day). He had recurrent thoughts and voices
urging him to yell at people and slap his wife. Other
symptoms consisted of sudden onset of severe, violent
and hostile moods, agitation and feeling that he was
another person. He also experienced excessive seda-
tion, restlessness, confusion and fear. These symptoms
resolved completely within 48 hours after discontinu-
ation of topiramate.
Case 5
A 30-year-old man had a 15-year history of post-
traumatic complex partial seizures. He had a history of
aggressive and agitated behavior with suicidal thoughts
over the past few years, but had repeatedly refused
treatment for these symptoms. He was averaging 2–
3 CPS/day. Topiramate was added at an initial dose
of 50 mg q.d. to a treatment regimen of vigabatrin,
phenobarbital, and phenytoin. Topiramate side-effects
developed at a dose of 200 mg b.i.d. (400 mg/day) at a
time when his seizures had been totally controlled for
over three weeks. These consisted of confusion, agita-
tion, bizarre thinking, obsession, hearing voices, suici-
dal ideation, thinking Jesus was behind the mass sui-
cide which had just occurred in California and that he
came to pick up all dead Catholics. He secretly started
carrying a gun. He was admitted to a psychiatric hospi-
tal involuntarily. A partial resolution of the symptoms
occurred with neuroleptic medication. Treatment with
topiramate was continued since he was seizure-free on
topiramate.
He was discharged from the psychiatric hospital after
one month and when seen in the Epilepsy Clinic one
month later was calm, pleasant, and free of all psychotic
symptoms. At that time he was receiving antipsychotic
medications as well as topiramate 200 mg b.i.d. and
phenytoin. He has remained seizure-free and stable for
the next six months. An increase of dose of topiramate
from 400 mg/day to 600 mg/day later resulted in the
recurrence of above symptoms.
Discussion
An association between psychosis and epilepsy has
been recognized for a long time. Some of the antiepilep-
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(Suppl. 6).tic drugs (AEDs) have also been implicated in vari-
ous psychiatric symptoms including symptoms of psy-
chosis in patients with and without a prior history of
psychiatric illness. Three of our patients had no history
of psychiatric illness. The time of onset of psychotic
symptoms in our patients was variable although a sim-
ilar slow titration method was used in all cases, in no
case faster than 25–50 mg increases per week. The rec-
ommended initial dose and titration rate of topiramate
during the immediate post-marketing period was 50 mg
per day to be increased every week by 50 mg per day
and as tolerated.
The symptoms of psychosis were unlikely to be post-
ictal psychosis for two reasons: first, in four patients
the onset of symptoms was rather slow and evolved
over 1–2 weeks, and secondly, there was no history
of a seizure for at least three weeks before the onset
of psychotic symptoms in three patients. One patient
never had any seizures while on topiramate therapy and
one other patient had only one complex partial seizure
during 18 days of topiramate treatment. Complex par-
tial status epilepticus was not a consideration based on
clinical examinations. Two patients had normal EEGs
at the time of symptoms.
Carbamazepine has been implicated in the devel-
opment of psychosis in four patients in one report2.
Only one of our five patients was on carbamazepine
at the time of topiramate treatment. One patient who
had a history of psychiatric disease was on three AEDs
including vigabatrin. Vigabatrin has been reported to
have psychosis as a side-effect1. Two other patients
were not on any AEDs when topiramate treatment was
begun. These facts suggest that a combination of topira-
mate with other AEDs, implicated in the development
of psychosis in the past, may not be the sole explanation
for the development of symptoms of psychosis in our
patients. Topiramate shares a GABAergic action with
vigabatrin, gabapentin, and tiagabine, along with its
other actions as a sodium channel blocker and antiglu-
tamatergic activity. Vigabatrin has been reported to be
responsible for the development of psychosis along
with various other psychiatric symptoms. Gabapentin
has been reported to cause significant cognitive impair-
ment in children4. However, the underlying mechanism
for these side-effects is unclear.
The concept of forced normalization has been de-
bated substantially in the literature as a hypothesis for
the development of psychiatric symptoms in epilep-
tic patients5. This concept is mostly concerned with
the normalization of EEG in patients with previous
EEGs showing epileptiform abnormality who develop
clinical behavioral abnormality6, 7. We were unable torecord serial EEGs in our patients, therefore this possi-
bility was considered but could not be excluded or con-
firmed. Patients 3 and 4 had a normal EEG at the onset
of symptoms of psychosis. Patient 4 also had a normal
24-hour long term video/EEG study three week prior to
onset of these symptoms. Three patients had no history
of psychiatric illness. Only one patient with a history
of psychiatric illness was having frequent seizures and
did achieve complete seizure control concomitant with
the development of psychosis. Improvement of symp-
toms on reduction of dose in one patient and recurrence
of the symptoms in another patient on increasing the
dose of topiramate may suggest dose related effects of
this medication on symptoms of psychosis and other
psychiatric symptoms in some patients.
Conclusions
Although the underlying mechanism and precipitating
factors for the development of symptoms of psychosis
are not clear in these patients treated with topiramate,
physicians should be aware of this potential side-effect.
It has also been recently reported by others8. Psychosis
resolves completely with discontinuation or reduction
of topiramate dose, and can also respond to appropriate
neuroleptic medications.
Although it may be judicious to avoid the use of top-
iramate in patients with a history of psychosis, this ad-
verse effect can develop in patients with no psychiatric
history.
